VANCOUVER, British Columbia — Tekmira Pharmaceuticals Corporation , a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented clinical results …

More here:
Tekmira's LNP Technology Enables Alnylam's Positive ALN-TTR02 Clinical Data